The acquisition of Luminex Corporation (LMNX) by Italy's Diasorin has been completed, ending the stock market listing of the US Company. DiaSorin agreed to merge with Luminex for $37 cash per share, or a total value of $1.8 billion.
Luminex last increased its quarterly dividend by 50.0 percent to $0.06 per share in 2019. This was the first dividend hike since a quarterly dividend was initiated in 2017.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries.